Comparison of two injection treatments with conventional management in treatment of knee pain

Platelet rich plasma (PRP) vs Prolotherapy in knee osteoarthritis: A single-center randomized controlled trial - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/100407

Enrollment

210

Registered

2026-01-06

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M179- Osteoarthritis of knee, unspecified

Interventions

Intervention1: Dextrose prolotherapy: 25% Dextrose is diluted with Bupivacaine and injected into tender points periarticularly around the knee Intervention2: Platelet Rich Plasma (PRP): Intraarticular

Eligibility

Inclusion criteria

Inclusion criteria: 1. Knee osteoarthritis diagnosed according to American College of Rheumatology criteria 2. Kellegren-Lawerence grades 2 and 3 on x-ray imaging 3. Knee pain for more than 3 months not responding to conservative management

Exclusion criteria

Exclusion criteria: 1. Presence of knee effusion 2. Local infection at the injection site 3. Evidence of systemic infection 4. Previous diagnosis of inflammatory arthropathy

Design outcomes

Primary

Measure	Time frame
Visual Analog ScaleTimepoint: Before the first injection 2 weeks, 6 weeks and 3 months after the first injection	—

Secondary

Measure	Time frame
Western Ontario and McMaster Universities Osteoarthritis indexTimepoint: Before the first injection 2 weeks, 6 weeks and 3 months after the first injection	—

Countries

India

Contacts

Public ContactDachepalli Satya Sreekar

All India Institute of Medical Sciences, Bibinagar

sreekardachepalli@gmail.com7306980044

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026